HealthPharmaceuticals
CVS Adds Zepbound and Foundayo to Drug Plans
CVS Health is reinstating coverage for Eli Lilly's Zepbound and adding coverage for the anti-obesity pill Foundayo, expanding weight-loss tr...
12 days ago
HealthPharmaceuticals
VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA
about 1 year agoUS
Phathom Pharmaceuticals (Nasdaq: PHAT) announced that the FDA has approved its Citizen Petition, granting VOQUEZNA® (vonoprazan) tablets 10 years of New Chemical Entity exclusivity, extending until May 3, 2032. This decision corrects the Orange Book to reflect the proper exclusivity period for this treatment of gastrointestinal diseases.
Key Insights
•
The FDA has granted VOQUEZNA® (vonoprazan) tablets market exclusivity until May 3, 2032.
•
VOQUEZNA® is a first-in-class potassium-competitive acid blocker (PCAB) used to treat heartburn associated with Non-Erosive GERD and Erosive GERD, as well as H. pylori infection.
•
This exclusivity protects Phathom Pharmaceuticals' investment and market position for VOQUEZNA®.
•
Why this matters: This decision ensures that Phathom Pharmaceuticals will have a longer period to capitalize on its innovative treatment, potentially leading to increased revenue and further research in gastrointestinal therapies.
In-Depth Analysis
On June 6, 2025, Phathom Pharmaceuticals announced a favorable decision from the FDA regarding VOQUEZNA®'s market exclusivity. The FDA approved Phathom's Citizen Petition, ensuring that VOQUEZNA® (vonoprazan) tablets will have 10 years of New Chemical Entity exclusivity, lasting until May 3, 2032. This exclusivity period is crucial for Phathom as it commercializes VOQUEZNA® for treating gastrointestinal diseases.
VOQUEZNA® is a first-in-class potassium-competitive acid blocker (PCAB) used for:
•
Relief of heartburn associated with Non-Erosive GERD in adults.
•
Healing and maintenance of healing of Erosive GERD in adults.
•
Treatment of H. pylori infection in adults (as part of VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®).
This FDA decision provides Phathom Pharmaceuticals with a significant competitive advantage, protecting their market position and encouraging further investment in gastrointestinal treatments. Investors and patients alike benefit from the assurance of continued availability and development of this innovative therapy.
FAQs
•
Q: What is VOQUEZNA®?
VOQUEZNA® (vonoprazan) is a first-in-class potassium-competitive acid blocker (PCAB) used to treat gastrointestinal diseases, including GERD and H. pylori infection.
•
Q: What does the FDA exclusivity mean for Phathom Pharmaceuticals?
The 10-year exclusivity means that Phathom Pharmaceuticals will have exclusive rights to market VOQUEZNA® until May 3, 2032, without competition from generic versions.
Key Takeaways
•
VOQUEZNA® has received a 10-year market exclusivity extension from the FDA, ensuring its availability until 2032.
•
This medication is used to treat common gastrointestinal issues like GERD and H. pylori infection.
•
Phathom Pharmaceuticals will continue to develop and commercialize VOQUEZNA®, benefiting patients and investors.
Discussion
What are your thoughts on the FDA's decision to extend VOQUEZNA®'s exclusivity? Share this article with others who need to stay ahead of this trend!
Related Articles
HealthPharmaceuticals
Novo Nordisk Expands Semaglutide Studies for Alcohol Use Disorder and Obesity
Novo Nordisk is broadening its research into semaglutide, originally developed for diabetes and obesity, to explore its potential in treatin...
about 1 month ago
HealthPharmaceuticals
NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment
After more than four decades, a new prescription medicine has emerged to combat motion sickness. Vanda Pharmaceuticals has announced the U.S...
about 1 month ago
HealthPharmaceuticals
TrumpRx Expands with AbbVie and Genentech, Raising Pricing Questions
Two major pharmaceutical companies, AbbVie and Genentech, are set to launch their medications on the TrumpRx platform, offering discounted p...
2 months ago
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer